as 07-26-2024 4:00pm EST
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Founded: | 2012 | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 5.6B | IPO Year: | 2015 |
Target Price: | $111.78 | AVG Volume (30 days): | 4.6M |
Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.94 | EPS Growth: | N/A |
52 Week Low/High: | $8.28 - $99.41 | Next Earning Date: | 07-24-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
ZANTE GREG | VKTX | Chief Financial Officer | May 3 '24 | Sell | $73.49 | 3,101 | $227,886.60 | 238,509 | SEC Form 4 |
ZANTE GREG | VKTX | Chief Financial Officer | May 3 '24 | Sell | $74.44 | 45,570 | $3,392,444.98 | 192,939 | SEC Form 4 |
ZANTE GREG | VKTX | Chief Financial Officer | May 3 '24 | Sell | $75.49 | 17,238 | $1,301,241.46 | 175,701 | SEC Form 4 |
ZANTE GREG | VKTX | Chief Financial Officer | May 3 '24 | Sell | $76.07 | 847 | $64,434.93 | 174,854 | SEC Form 4 |
Mancini Marianna | VKTX | Chief Operating Officer | May 1 '24 | Sell | $76.40 | 23,746 | $1,814,301.26 | 606,187 | SEC Form 4 |
Mancini Marianna | VKTX | Chief Operating Officer | May 1 '24 | Sell | $77.49 | 26,142 | $2,025,829.85 | 580,045 | SEC Form 4 |
Mancini Marianna | VKTX | Chief Operating Officer | May 1 '24 | Sell | $78.65 | 105,343 | $8,284,974.13 | 474,702 | SEC Form 4 |
Mancini Marianna | VKTX | Chief Operating Officer | May 1 '24 | Sell | $79.29 | 119,946 | $9,511,058.10 | 354,756 | SEC Form 4 |
Mancini Marianna | VKTX | Chief Operating Officer | May 1 '24 | Sell | $80.08 | 6,248 | $500,310.47 | 348,508 | SEC Form 4 |
Lian Brian | VKTX | President & CEO | Feb 9 '24 | Sell | $29.90 | 45,000 | $1,345,500.00 | 2,139,882 | SEC Form 4 |
Lian Brian | VKTX | President & CEO | Feb 8 '24 | Sell | $25.75 | 49,079 | $1,263,784.25 | 2,264,882 | SEC Form 4 |
Lian Brian | VKTX | President & CEO | Feb 8 '24 | Sell | $25.95 | 60,000 | $1,557,000.00 | 2,344,882 | SEC Form 4 |
Lian Brian | VKTX | President & CEO | Feb 8 '24 | Sell | $26.95 | 80,000 | $2,156,000.00 | 2,264,882 | SEC Form 4 |
Lian Brian | VKTX | President & CEO | Feb 8 '24 | Sell | $27.45 | 40,000 | $1,098,000.00 | 2,224,882 | SEC Form 4 |
Lian Brian | VKTX | President & CEO | Feb 8 '24 | Sell | $28.90 | 40,000 | $1,156,000.00 | 2,184,882 | SEC Form 4 |
Rouan Sarah Kathryn | VKTX | Director | Feb 8 '24 | Sell | $28.05 | 25,000 | $701,250.00 | 0 | SEC Form 4 |
Lian Brian | VKTX | President & CEO | Jan 31 '24 | Sell | $24.45 | 40,000 | $978,000.00 | 2,309,882 | SEC Form 4 |
Lian Brian | VKTX | President & CEO | Jan 31 '24 | Sell | $24.95 | 45,000 | $1,122,750.00 | 2,264,882 | SEC Form 4 |
Lian Brian | VKTX | President & CEO | Jan 30 '24 | Sell | $23.95 | 35,000 | $838,250.00 | 2,264,882 | SEC Form 4 |
Rouan Sarah Kathryn | VKTX | Director | Jan 19 '24 | Sell | $23.05 | 30,000 | $691,500.00 | 0 | SEC Form 4 |
ZANTE GREG | VKTX | Chief Financial Officer | Jan 3 '24 | Sell | $17.90 | 15,000 | $268,500.00 | 180,730 | SEC Form 4 |
VKTX Breaking Stock News: Dive into VKTX Ticker-Specific Updates for Smart Investing
Yahoo Finance Video
6 hours ago
Clinical Trials Arena
9 hours ago
Yahoo Finance Video
9 hours ago
Motley Fool
a day ago
MT Newswires
a day ago
MT Newswires
a day ago
Investopedia
a day ago
Motley Fool
a day ago
The information presented on this page, "VKTX Viking Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.